Actinium-225 Production for Medical Applications Using Best Cyclotron Systems — a Team BestGlobal Company

Actinium-225 Production for Medical Applications Using Best Cyclotron Systems — a Team BestGlobal Company

Washington, DC, USA – (EIN PRESSWIRE) – December 6, 2022

Best Cyclotron Systems, a TeamBest Global (TBG) Company, has designed and installed a variety of cyclotrons for medical, industrial and research applications ranging from energy 1 MeV to 70 MeV.  Many of these cyclotrons can be used for production of Actinium-225, an isotope potentially useful for therapeutic applications.

There has been great interest in targeted alpha therapy using Actinium-225 (Ac-225).  In particular, prostate cancer patients have been treated Ac-225 with notable success.  Ac-225 attached monoclonal antibody products have been used in clinical trials for treatment of leukemia.  It is expected that targeted alpha therapy can lead to positive outcome, hence global efforts towards the production of Ac-225 have increased substantially.

Ac-225 has a 10-day half-life and decays with the emission of an alpha particle, subsequently following a decay path with four alpha particles being emitted.  A large radiation dose can be delivered to the tumor site because of the very high Linear Energy Transfer (LET) of alpha particles.

Ac-225 can mainly be produced by two reactions.  One is a proton induced spallation reaction at 70 MeV or higher using thorium as the production target.  That reaction is accessible using the BEST B70 proton cyclotron.  The second reaction is the proton induced (p,2n) reaction on Radium-226 (Ra-226).  This reaction can be utilized at proton energies from 10 to 30 MeV and hence it is a candidate for production on the BEST B15, B20, B25 and B35 MeV cyclotrons.

For more information, Click here to view the original press release.

Click here to download the PDF.